Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (58)

I-01Nurul Azrin Abd Rahman

A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax Volunteer-Infection Study

Wednesday 09:50-11:15

I-02Mahmoud Abdelwahab

Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis

Wednesday 09:50-11:15

I-06Ahmed Aliyu Abulfathi

External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package

Wednesday 09:50-11:15

I-11Marie Alexandre

Modeling viral rebound in HIV therapeutic vaccine studies

Wednesday 09:50-11:15

I-15Vincent Aranzana-Climent

Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii

Wednesday 09:50-11:15

I-23Rami Ayoun Alsoud

Simultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy

Wednesday 09:50-11:15

I-56David Busse

Analysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling

Wednesday 09:50-11:15

I-58Unai Caballero

Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris

Wednesday 09:50-11:15

I-70Alexia Chauzy

Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria

Wednesday 09:50-11:15

I-72Lu Chen

Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis

Wednesday 09:50-11:15

I-73Maxwell Chirehwa

Population pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients

Wednesday 09:50-11:15

I-75Palang Chotsiri

Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity

Wednesday 09:50-11:15

I-78Perrine Courlet

Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV.

Wednesday 09:50-11:15

II-10Donghwan Lee

Effect of Pharmacokinetic Model Misspecification on Antibiotic Probability of Target Attainment Predicted by Monte Carlo Simulation

Wednesday 15:10-16:40

II-21Feiyan Liu

Modeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide

Wednesday 15:10-16:40

II-67Taniya Paiboonvong

Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid

Wednesday 15:10-16:40

II-68Semra Palic

Neopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis

Wednesday 15:10-16:40

II-81Mélanie Prague

In Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies

Wednesday 15:10-16:40

II-85Chetan Rathi

Model-Informed selection of doses and sample size for a Phase 2a POC study of GSK3640254, a next generation HIV-1 maturation inhibitor

Wednesday 15:10-16:40

III-04Christer Rimmler

Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models

Thursday 09:55-11:20

III-05Viktor Rognås

Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections

Thursday 09:55-11:20

III-06Federico Romano

Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine

Thursday 09:55-11:20

III-26Tomas Sou

Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin

Thursday 09:55-11:20

III-29Gabriel Stillemans

Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients

Thursday 09:55-11:20

III-31Herbert Struemper

Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus

Thursday 09:55-11:20

III-34Jesper Sundell

Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV

Thursday 09:55-11:20

III-35Budi Octasari Susanto

Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development

Thursday 09:55-11:20

III-38Lénaïg Tanneau

Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients

Thursday 09:55-11:20

III-39Joel Tarning

Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria

Thursday 09:55-11:20

III-42Anders Thorsted

Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies

Thursday 09:55-11:20

III-43Tjokosela Tikiso

A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications.

Thursday 09:55-11:20

III-48Sami Ullah

Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function

Thursday 09:55-11:20

III-53Stijn van Beek

Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients

Thursday 09:55-11:20

III-58Rob van Wijk

Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae

Thursday 09:55-11:20

III-61Luka Verrest

Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients

Thursday 09:55-11:20

III-65Wenyi Wang

Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes

Thursday 09:55-11:20

III-67Zhigang Wang

A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo

Thursday 09:55-11:20

III-71Ferdinand Weinelt

A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients

Thursday 09:55-11:20

III-73Quirin Werthner

Network-based mathematical modelling of HPV transmission and cervical cancer in Germany.

Thursday 09:55-11:20

III-76Justin Wilkins

Population Pharmacokinetics analysis of M5717, a novel antimalarial agent

Thursday 09:55-11:20

III-80Xia Li

A Physiologically-Based Pharmacokinetic Model of Voriconazole

Thursday 09:55-11:20

III-81Rujia Xie

Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections

Thursday 09:55-11:20

III-84Jinqiu Yin

Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections

Thursday 09:55-11:20

III-88Chenyan Zhao

Colistin to overcome resistance to ciprofloxacin – Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model

Thursday 09:55-11:20

IV-12Alan Faraj

Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients

Thursday 15:25-16:50

IV-18Jose Francis

A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure

Thursday 15:25-16:50

IV-20Aline Fuchs

Assessment of translation of PKPD relationship from animal to human for malaria compounds

Thursday 15:25-16:50

IV-25Kamunkhwala Gausi

Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings

Thursday 15:25-16:50

IV-38Jinju Guk

Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers

Thursday 15:25-16:50

IV-41Felix Hammann

Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital

Thursday 15:25-16:50

IV-51Richard Höglund

Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach

Thursday 15:25-16:50

IV-58Luis Ilia

Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid

Thursday 15:25-16:50

IV-59Khalid Iqbal

Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin

Thursday 15:25-16:50

IV-61Kris Oliver Jalusic

Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients

Thursday 15:25-16:50

IV-65Mats Jirstrand

A challenge model of TNFα turnover with LPS provocations and drug intervention

Thursday 15:25-16:50

IV-78Aida Kawuma

Dolutegravir pharmacokinetics in co-administration with rifampicin.

Thursday 15:25-16:50

IV-84Dohyun Kim

Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference

Thursday 15:25-16:50

IV-86Franziska Isabelle Kluwe

Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration

Thursday 15:25-16:50